Details
Category: Volume 08 Issue 07 July 2020
Hits: 1044

Title: A Review of Corona Virus Disease-2019

Authors: A.Mishal, R.Saravanan, S.Sakthi Atchitha, K.Santhiya, M.Rithika, S.Sanju Menaka, T.Thiruvalluvan

 DOI: https://dx.doi.org/10.18535/jmscr/v8i7.59

Abstract

Epidemic often occurs with zoonotic origin, viruses such as Ebola, Zika and SARS outbreak serves as an example. A zoonotic virus which belongs to Coronaviridae family emerged in Wuhan, China spreads around the world through human-human transmission by having ACE II receptor as binding site and was named as SARS CoV-2.Clinically they are diagnosed with a confirmatory molecular test, blood test, CT scan to the people who has symptoms of breathlessness, fever (for more than one week), cough, sore throat, headache, anosmia, ageusia and in asymptomatic condition person’s travelling history to infected countries or having close contact with infected patient helps in diagnosis. Till now there is no officially recognised treatment for COVID-19 which was managed by symptomatic relief and by some antiviral drug so, prevention plays an important role to supress the spread. Several preventive measures have been implemented by the health care workers and the government to reduce the spread of COVID-19 such as social distancing, self-quarantining, use of mask, personal hygiene and use of hand sanitizer were followed at community level

Keywords: Zoonotic virus, SARS CoV-2, COVID-19, ACE II receptor.

References

  1. Holmes, K. V. et al. Coronavirus receptor specificity. Adv. Exp. Med. Biol. 342, 261–266 (1993).
  2. Rota, P. A. et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394–1399 (2003).
  3. Bonavia, A., Zelus, B. D., Wentworth, D. E., Talbot, P. J. & Holmes, K. V. Identification of areceptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E. J. Virol. 77,2530–2538 (2003).
  4. Crackower, M. A. et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822–828 (2002).
  5. Leung, W. K. et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 125, 1011–1017 (2003).
  6. Rahman A, Sarkar A. Risk factors for fatal middle east respiratory syndrome coronavirus infections in Saudi Arabia: analysis of the WHO Line List, 2013–2018. Am J Public Health 2019;109 (9):1288–93.
  7. Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al.Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med 2020.
  8. Paden C, Yusof M, Al Hammadi Z, Queen K, Tao Y, Eltahir Y, et al. Zoonoticorigin and transmission of Middle East respiratory syndrome coronavirus in the UAE. Zoonoses Public Health 2018;65 (3):322–33.
  9. Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, et al. Dipeptidylpeptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013;495 (7440):251–4.
  10. Bertram S, Glowacka I, Müller MA, Lavender H, Gnirss K, Nehlmeier I, et al.Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol 2011;85 (24):13363–72.
  11. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition anddivergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020.
  12. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novelcoronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020;1–4.
  13. Geo-Vax. Geovax and bravovax (wuhan, china) to collaborate on development of coronavirus vaccine. [cited 2020 3 March]; Available from: https://www.geovax.com/news/geovax-and-bravovax-wuhan-china-to-collaborate-ondevelopment-of-coronavirus-vaccine.
  14. World Health Organization. Laboratory testing of human suspectedcases of novel coronavirus (nCoV) infection [published online aheadof print January 21, 2020]. https://apps.who.int/iris/bitstream/handle/10665/330374/WHO‐2019‐nCoV‐laboratory‐2020.1‐eng.pdf
  15. World Health Organization. Novel Coronavirus (2019‐nCoV) situation report‐2 [published online ahead of print January 21, 2020]. https://www.who.int/docs/default‐source/coronaviruse/situation‐reports/20200122‐sitrep‐2‐2019‐ncov.pdf
  16. World Health Organization. Middle East respiratory syndrome coronavirus (MERS‐CoV) [published online ahead of print January 21,2020]. https://www.who.int/emergencies/mers‐cov/en/
  17. World Health Organization. WHO MERS global summary and assessment of risk [published online ahead of print January 21, 2020]. https://www.who.int/csr/disease/coronavirus_infections/risk‐assessment‐august‐2018.pdf?ua=1
  18. Yoneyama M, Fujita T. RNA recognition and signal transduction by RIG‐I‐like receptors. Immunol Rev. 2009;227 (1):54‐65.
  19. Strasser D, Neumann K, Bergmann H, et al. Syk kinase‐coupled C‐typelectin receptors engage protein kinase C‐sigma to elicit Card9 adaptormediated innate immunity. Immunity. 2012;36(1):32‐42.
  20. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan,China, of novel coronavirus-infected pneumonia. N Engl J Med 2020. https://doi.org/10.1056/NEJMoa2001316.
  21. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
  22. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group ofpatients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.
  23. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–5.
  24. World Health Organization. Coronavirus disease [COVID-19]Technical Guidance: Infection Prevention and Control. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/infection-prevention-and-control. Accessed 20 Feb 2020.
  25. Lu, C.W. Stratton, Y.W. Tang, Outbreak of pneumonia of unknown etiology inwuhan China: the mystery and the miracle, J. Med. Virol. 92 (4) (2020) 401–402, https://doi.org/10.1002/jmv.25678.
  26. Lei, J. Li, X. Li, X. Qi, CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia, Radiology (2020) 200236, https://doi.org/10.1148/radiol.2020200236.
  27. Assiri, J.A. Al-Tawfiq, A.A. Al-Rabeeah, F.A. Al-Rabiah, S. Al-Hajjar, A. Al-Barrak, et al., Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study, Lancet Infect. Dis. 13 (2013) 752–761.
  28. Ji, W. Wang, X. Zhao, J. Zai, X. Li, Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human, J. Med. Virol. 92 (4) (2020) 433–440, https://doi.org/10.1002/jmv.25682.
  29. Wan, J. Shang, R. Graham, R.S. Baric, F. Li, Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS, J. Virol. (2020), https://doi.org/10.1128/JVI.00127-20.
  30. S. Hui, E. IA, T.A. Madani, F. Ntoumi, R. Kock, O. Dar, et al., The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China, Int. J. Infect. Dis. 91 (2020) 264–266.
  31. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, et al., Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019nCoV) in Vitro, Cell research, 2020.
  32. Toots, J.J. Yoon, R.M. Cox, M. Hart, Z.M. Sticher, N. Makhsous, et al., Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia, Sci. Transl. Med. (2019) 11.
  33. H. Jin, L. Cai, Z.S. Cheng, H. Cheng, T. Deng, Y.P. Fan, et al., A rapid adviceguideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version), Mil. Med. Res. 7 (2020) 4.\
  34. A. Jaimes, J.K. Millet, A.E. Stout, N.M. Andre, G.R. Whittaker, A tale of two viruses: the distinct spike glycoproteins of feline coronaviruses, Viruses 12 (2020).
  35. S. Hui, E. IA, T.A. Madani, F. Ntoumi, R. Kock, O. Dar, et al., The continuing 2019nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China, Int. J. Infect. Dis. 91 (2020) 264–266.
  36. Cui, F. Li, Z.L. Shi, Origin and evolution of pathogenic coronaviruses, Nat. Rev. Microbiol. 17 (2019) 181–192.
  37. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet 395 (10223) (2020) 507–513, https://doi.org/10.1016/S01406736(20)30211-7.
  38. Cui, F. Li, Z.L. Shi, Origin and evolution of pathogenic coronaviruses, Nat. Rev. Microbiol. 17 (2019) 181–192.
  39. Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting. Wuhan. Emerging Microbes & Infections 2020;9(1):221–36.
  40. Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, et al. Dipeptidylpeptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495(7440):251–4.

Corresponding Author

A.Mishal

Department of Pharmacy Practice, Jaya College of Paramedical Sciences, College of Pharmacy, Thiruninravur,  Chennai – 602024, INDIA